This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Alzheimer's Disease & Dementia Conference" (Dementia 2025) June 05-07, 2025 | Hybrid Event has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at dementia@magnusconference.com or call + 1 (702) 988 2320.
New diagnostic and therapeutic tools combining nanotechnology have been developed in recent medical research, which are beneficial to the specific transport and absorption of drugs and contrast agents to the brain, as well as promoting the regeneration of damaged neurons to limit or reverse neurological disorders. As a common neurological condition, dementia affected 46.8 million individuals globally in 2015, with that figure expected to rise to 131.5 million by 2050. Early identification is critical for efficient treatment of AD since neuro invasiveness and degenerative changes begin before the onset of symptoms. To detect and identify amyloid plaques, most investigations use magnetic resonance imaging (MRI) using contrast-doped NPs or tagging NPs with fluorescent probes. To combat neurodegenerative disorders, nanotechnology can be applied into neuroscience.
Important Alert:
X
Title : Early clinical development of modified P8 for the treatment of alzheimer’s disease
Nazneen N Dewji, Cenna Biosciences Inc, United States
Title : Who cares for the carers
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Memory should be the primary endpoint in early AD
Matthias W Riepe, Ulm University, Germany
Title : Down’s syndrome (trisomy 21) and alzheimer disease: A common medical and scientific fight
London Jacqueline, Paris Diderot University, France
Title : Quality of life children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Efficacy of transcranial photobiomodulation in mild cognitive impairment and early alzheimer’s Disease: A randomized controlled study
Hyelim Chun, St.Peter’s General Hospital, Korea, Republic of